Erste Asset Management GmbH Buys Shares of 91,020 IQVIA Holdings Inc. (NYSE:IQV)

Erste Asset Management GmbH purchased a new position in shares of IQVIA Holdings Inc. (NYSE:IQV) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 91,020 shares of the medical research company’s stock, valued at approximately $21,505,000.

Several other large investors have also bought and sold shares of IQV. Bellevue Group AG increased its holdings in IQVIA by 41.0% in the 3rd quarter. Bellevue Group AG now owns 129,827 shares of the medical research company’s stock worth $30,765,000 after acquiring an additional 37,744 shares during the last quarter. PDT Partners LLC purchased a new stake in shares of IQVIA during the third quarter valued at approximately $853,000. Captrust Financial Advisors raised its holdings in shares of IQVIA by 30.8% during the third quarter. Captrust Financial Advisors now owns 8,188 shares of the medical research company’s stock valued at $1,940,000 after acquiring an additional 1,927 shares in the last quarter. Icon Wealth Advisors LLC raised its holdings in IQVIA by 88.3% in the third quarter. Icon Wealth Advisors LLC now owns 981 shares of the medical research company’s stock worth $232,000 after purchasing an additional 460 shares in the last quarter. Finally, Northwest & Ethical Investments L.P. bought a new position in IQVIA in the third quarter worth $3,175,000. 89.62% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts have issued reports on IQV shares. JPMorgan Chase & Co. dropped their target price on IQVIA from $279.00 to $240.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 5th. Robert W. Baird dropped their price objective on IQVIA from $256.00 to $223.00 and set a “neutral” rating for the company in a report on Friday, November 1st. Evercore ISI reduced their price target on IQVIA from $270.00 to $265.00 and set an “outperform” rating for the company in a research report on Tuesday, October 8th. Morgan Stanley reduced their target price on IQVIA from $280.00 to $265.00 and set an “overweight” rating on the stock in a research report on Monday, November 4th. Finally, Redburn Atlantic initiated coverage on IQVIA in a research note on Monday, October 14th. They set a “buy” rating and a $276.00 price target on the stock. Five research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $256.50.

IQVIA Trading Down 0.3 %

Shares of IQVIA stock opened at $200.84 on Friday. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81. IQVIA Holdings Inc. has a 1 year low of $187.62 and a 1 year high of $261.73. The company has a market capitalization of $36.45 billion, a P/E ratio of 26.36, a P/E/G ratio of 2.07 and a beta of 1.51. The business has a 50 day moving average price of $218.67 and a 200 day moving average price of $226.17.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.